Komori
Share Issuance and Disposal2796Pharmarise Holdings CorporationRetail

Notice of Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation

Payment has been completed for the disposal of 141,310 treasury shares to 6 directors as restricted stock compensation.

Worth reading
27Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
141310
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposal of treasury shares as restricted stock compensation

Who receives how much141,310Shares

141,310 common shares of the Company (treasury shares)

6 directors of the Company: 141,310 shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥505 per share
Total issue value

¥71,361,550

Categories and Number of Persons Covered
6 directors of the Company (excluding outside directors): 141,310 shares
Payment date
5 October 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposal of treasury shares as restricted stock compensation
Number of shares to be issued or disposed of141,310 common shares of the Company (treasury shares)
Issue price and disposal price¥505 per share
Total issue value¥71,361,550
Payment date5 October 2026
Intended allottee6 directors of the Company: 141,310 shares
Categories and Number of Persons Covered6 directors of the Company (excluding outside directors): 141,310 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the payment procedures for the disposal of treasury shares approved at the Board of Directors meeting held on 17 September 2026 have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation | Pharmarise Holdings Corporation (2796) timely disclosure | Komori